For a vaccine to work, it has to raise antibodies in the immunized – antibodies that are primed to neutralize subsequent intruders.
For a vaccine to work, it has to raise antibodies in the immunized – antibodies that are primed to neutralize subsequent intruders. For a vaccine to be safe, it has to do so for the vast majority without major side effects or reactions. A new vaccine candidate for HIV is facing those familiar challenges in early-stage clinical trials, succeeding in one aspect but encountering some hurdles in the other. It's still progress though, as its developers have reformulated the vaccine to improve its safety in future studies – while their latest results show how the vaccine successfully generates broadly neutralizing antibodies in a small number of people.
Continue Reading.
